Improved HIV Envelope Glycoprotein Immunogens, EP3672983A1, Amsterdam UMC

The EPO published EP3672983A1, a European patent application (A1 publication) for improved HIV envelope glycoprotein immunogens filed by Stichting Amsterdam UMC under IPC classification C07K 14/005. The patent application covers the immunogen composition with A61K 39/21 designation.

For biotechnology and pharmaceutical entities, this publication establishes intellectual property rights for Amsterdam UMC covering HIV envelope glycoprotein technology across all designated EU contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). Organizations engaged in HIV vaccine research or glycoprotein immunogen development should review Freedom to Operate positions.